


Supplementary information

Accelerated functional brain aging in pre-clinical familial Alzheimer's disease

Julie Gonneaud, Alex T. Baria, Alexa Pichet Binette, Brian A. Gordon, Jasmeer P. Chhatwal, Carlos Cruchaga, Mathias Jucker, Johannes Levin, Stephen Salloway, Martin Farlow, Serge Gauthier, Tammie L.S. Benzinger, John C. Morris, Randall J. Bateman, John C.S. Breitner, Judes Poirier, Etienne Vachon-Presseau, and Sylvia Villeneuve, Alzheimer's Disease Neuroimaging Initiative (ADNI), Dominantly Inherited Alzheimer Network (DIAN) Study Group, Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) Research Group


Supplementary Fig. 1 Correlation between the 10 graph metrics used as input in the neural network	page 2
Supplementary Fig. 2 Age prediction model with and without ComBat harmonization	page 3
Supplementary Table 1 Percentage of frames retained from resting-state fMRI scans in each cohort	page 4
Supplementary Table 2 Functional brain parcellation (based on Power and Petersen functional atlas)	page 5
Supplementary Table 3 Gene primers in DIAN	page 7
Supplementary Table 4 Gene primers in PREVENT-AD	page 8
Supplementary Methods Race/ethnicity of the different cohorts and Estimated years to symptom onset Small-worldness and resilience calculation	page 9 page 10
Supplementary Notes	page 11
Supplementary References	page 16

Supplementary Fig. 1



Supplementary Figure 1: Pearson correlations between the 10 graph metrics used as input in the neural network. The color-scale represents r-values; stronger positive correlations being represented by lighter (yellow) colors while darker (blue) colors correspond to stronger negative correlations.

Supplementary Fig. 2



Supplementary Figure 2. Age prediction from support vector machine models using original graph metrics as input (A) and age prediction from support vector machine models using harmonized graph metrics from ComBat as input. (B)

Supplementary Table 1. Percentage of frames retained from resting-state fMRI scans in each cohort

Cohort	Average % frames retained \pm SD
CamCAN	86.2 \pm 15.5
FCP-Cambridge	100 \pm 0
DIAN	93.8 \pm 12.0
Prevent-AD	85.0 \pm 17.2
ADNI	80.7 \pm 15.4
ICBM	96.76 \pm 8.0

SD: standard deviation

Supplementary Table 2. Functional brain parcellation (based on Power and Petersen functional atlas)

ROI	MNI space			Suggested System			ROI	MNI space			Suggested System		
	X	Y	Z					X	Y	Z			
13	-7	-52	61	Sensory/somatomotor Hand			74	-41	-75	26	Default mode		
14	-14	-18	40	Sensory/somatomotor Hand			75	5,6	67	-4	Default mode		
15	0,1	-15	47	Sensory/somatomotor Hand			76	8,4	48	-15	Default mode		
16	9,5	-2	45	Sensory/somatomotor Hand			77	-13	-40	0,9	Default mode		
17	-7	-21	65	Sensory/somatomotor Hand			78	-18	63	-9	Default mode		
18	-7	-33	72	Sensory/somatomotor Hand			79	-46	-61	21	Default mode		
19	13	-33	75	Sensory/somatomotor Hand			80	43	-72	28	Default mode		
20	-54	-23	43	Sensory/somatomotor Hand			81	-44	12	-34	Default mode		
21	29	-17	71	Sensory/somatomotor Hand			82	46	16	-30	Default mode		
22	9,9	-46	73	Sensory/somatomotor Hand			86	-44	-65	35	Default mode		
23	-23	-30	72	Sensory/somatomotor Hand			87	-39	-75	44	Default mode		
24	-40	-19	54	Sensory/somatomotor Hand			88	-7	-55	27	Default mode		
25	29	-39	59	Sensory/somatomotor Hand			89	5,9	-59	35	Default mode		
26	50	-20	42	Sensory/somatomotor Hand			90	-11	-56	16	Default mode		
27	-38	-27	69	Sensory/somatomotor Hand			91	-3	-49	13	Default mode		
28	20	-29	60	Sensory/somatomotor Hand			92	7,9	-48	31	Default mode		
29	44	-8	57	Sensory/somatomotor Hand			93	15	-63	26	Default mode		
30	-29	-43	61	Sensory/somatomotor Hand			94	-2	-37	44	Default mode		
31	10	-17	74	Sensory/somatomotor Hand			95	11	-54	17	Default mode		
32	22	-42	69	Sensory/somatomotor Hand			96	52	-59	36	Default mode		
33	-45	-32	47	Sensory/somatomotor Hand			97	23	33	48	Default mode		
34	-21	-31	61	Sensory/somatomotor Hand			98	-10	39	52	Default mode		
35	-13	-17	75	Sensory/somatomotor Hand			99	-16	29	53	Default mode		
36	42	-20	55	Sensory/somatomotor Hand			100	-35	20	51	Default mode		
37	-38	-15	69	Sensory/somatomotor Hand			101	22	39	39	Default mode		
38	-16	-46	73	Sensory/somatomotor Hand			102	13	55	38	Default mode		
39	2,4	-28	60	Sensory/somatomotor Hand			103	-10	55	39	Default mode		
40	3,5	-17	58	Sensory/somatomotor Hand			104	-20	45	39	Default mode		
41	38	-17	45	Sensory/somatomotor Hand			105	5,9	54	16	Default mode		
42	-49	-11	35	Sensory/somatomotor Mouth			106	6,1	64	22	Default mode		
43	36	-9	14	Sensory/somatomotor Mouth			107	-7	51	-1	Default mode		
44	51	-6	32	Sensory/somatomotor Mouth			108	8,8	54	3,5	Default mode		
45	-53	-10	24	Sensory/somatomotor Mouth			109	-3	44	-9	Default mode		
46	66	-8	25	Sensory/somatomotor Mouth			110	7,5	42	-5	Default mode		
47	-3	2,4	53	Cingulo-opercular Task Control			111	-11	45	7,6	Default mode		
48	54	-28	34	Cingulo-opercular Task Control			112	-2	38	36	Default mode		
49	19	-8	64	Cingulo-opercular Task Control			113	-3	42	16	Default mode		
50	-16	-5	71	Cingulo-opercular Task Control			114	-20	64	19	Default mode		
51	-10	-2	42	Cingulo-opercular Task Control			115	-8	48	23	Default mode		
52	37	0,8	-4	Cingulo-opercular Task Control			117	-56	-13	-10	Default mode		
53	13	-1	70	Cingulo-opercular Task Control			118	-58	-30	-4	Default mode		
54	6,5	7,7	51	Cingulo-opercular Task Control			119	65	-31	-9	Default mode		
55	-45	0,1	8,8	Cingulo-opercular Task Control			120	-68	-41	-5	Default mode		
56	49	8,3	-1	Cingulo-opercular Task Control			121	13	30	59	Default mode		
57	-34	3,3	4,2	Cingulo-opercular Task Control			122	12	36	20	Default mode		
58	-51	8,3	-2	Cingulo-opercular Task Control			123	52	-2	-16	Default mode		
59	-5	18	34	Cingulo-opercular Task Control			124	-26	-40	-8	Default mode		
60	36	10	1,2	Cingulo-opercular Task Control			125	27	-37	-13	Default mode		
61	32	-26	13	Auditory			126	-34	-38	-16	Default mode		
62	65	-33	20	Auditory			127	28	-77	-32	Default mode		
63	58	-16	7,5	Auditory			128	52	6,8	-30	Default mode		
64	-38	-33	17	Auditory			129	-53	2,6	-27	Default mode		
65	-60	-25	14	Auditory			130	47	-50	29	Default mode		
66	-49	-26	5,2	Auditory			131	-49	-42	0,8	Default mode		
67	43	-23	20	Auditory			133	-2	-35	31	Memory retrieval		
68	-50	-34	26	Auditory			134	-7	-71	42	Memory retrieval		
69	-53	-22	23	Auditory			135	11	-66	42	Memory retrieval		
70	-55	-9	12	Auditory			136	4,2	-48	51	Memory retrieval		
71	56	-5	13	Auditory			137	-46	31	-13	Default mode		
72	59	-17	29	Auditory									
73	-30	-27	12	Auditory									

138	-10	11	67	Ventral attention
139	49	35	-12	Default mode

ROI	MNI space			Suggested System	ROI	MNI space			Suggested System
	X	Y	Z			X	Y	Z	
143	18	-47	-10	Visual	211	34	16	-8	Salience
144	40	-72	14	Visual	212	-11	26	25	Salience
145	8,5	-72	11	Visual	213	-1	15	44	Salience
146	-8	-81	7,4	Visual	214	-28	52	21	Salience
147	-28	-79	19	Visual	215	-0	30	27	Salience
148	20	-66	1,7	Visual	216	5,2	23	37	Salience
149	-24	-91	19	Visual	217	10	22	27	Salience
150	27	-59	-9	Visual	218	31	56	14	Salience
151	-15	-72	-8	Visual	219	26	50	27	Salience
152	-18	-68	4,8	Visual	220	-39	51	17	Memory retrieval
153	43	-78	-12	Visual	221	1,8	-24	30	Subcortical
154	-47	-76	-10	Visual	222	6,3	-24	-0	Subcortical
155	-14	-91	31	Visual	223	-2	-13	12	Subcortical
156	15	-87	37	Visual	224	-10	-18	7	Subcortical
157	29	-77	25	Visual	225	12	-17	7,5	Subcortical
158	20	-86	-2	Visual	226	-5	-28	-4	Subcortical
159	15	-77	31	Visual	227	-22	7,5	-5	Subcortical
160	-16	-52	-1	Visual	228	-15	3,6	8	Subcortical
161	42	-66	-8	Visual	229	31	-14	1,7	Subcortical
162	24	-87	24	Visual	230	23	10	1,5	Subcortical
163	5,6	-72	24	Visual	231	29	0,8	4	Subcortical
164	-42	-74	0,4	Visual	232	-31	-11	-0	Subcortical
165	26	-79	-16	Visual	233	15	4,9	7,2	Subcortical
166	-16	-77	34	Visual	234	8,6	-4	5,8	Subcortical
167	-3	-81	21	Visual	235	54	-43	22	Ventral attention
168	-40	-88	-6	Visual	236	-56	-50	9,9	Ventral attention
169	37	-84	13	Visual	237	-55	-40	14	Ventral attention
170	6,2	-81	6,1	Visual	238	52	-33	7,6	Ventral attention
171	-26	-90	3,1	Visual	239	51	-29	-4	Ventral attention
172	-33	-79	-13	Visual	240	56	-46	11	Ventral attention
173	37	-81	1,2	Visual	241	53	33	0,6	Ventral attention
174	-44	1,8	46	Fronto-parietal Task Control	242	-49	25	-1	Ventral attention
175	48	25	27	Fronto-parietal Task Control	251	9,6	-62	61	Dorsal attention
176	-47	11	23	Fronto-parietal Task Control	252	-52	-63	5,3	Dorsal attention
177	-53	-49	43	Fronto-parietal Task Control	255	47	-30	49	Sensory/somatomotor Hand
178	-23	11	64	Fronto-parietal Task Control	256	22	-65	48	Dorsal attention
179	58	-53	-14	Fronto-parietal Task Control	257	46	-59	3,9	Dorsal attention
180	24	45	-15	Fronto-parietal Task Control	258	25	-58	60	Dorsal attention
181	34	54	-13	Fronto-parietal Task Control	259	-33	-46	47	Dorsal attention
186	47	9,9	33	Fronto-parietal Task Control	260	-27	-71	37	Dorsal attention
187	-41	5,8	33	Fronto-parietal Task Control	261	-32	-1	54	Dorsal attention
188	-42	38	21	Fronto-parietal Task Control	262	-42	-60	-9	Dorsal attention
189	38	43	15	Fronto-parietal Task Control	263	-17	-59	64	Dorsal attention
190	49	-42	45	Fronto-parietal Task Control	264	29	-5	54	Dorsal attention
191	-28	-58	48	Fronto-parietal Task Control	265	-10	14	-2	Limbic
192	44	-53	47	Fronto-parietal Task Control	266	10	14	-2	Limbic
193	32	14	56	Fronto-parietal Task Control	267	-22	-2	-22	Limbic
194	37	-65	40	Fronto-parietal Task Control	268	26	-2	-22	Limbic
195	-42	-55	45	Fronto-parietal Task Control	269	-24	-14	-18	Limbic
196	40	18	40	Fronto-parietal Task Control	270	26	-14	-18	Limbic
197	-34	55	4,4	Fronto-parietal Task Control	271	-28	-34	-6	Limbic
198	-42	45	-2	Fronto-parietal Task Control	272	30	-34	-6	Limbic
199	33	-53	44	Fronto-parietal Task Control					
200	43	49	-2	Fronto-parietal Task Control					
201	-42	25	30	Fronto-parietal Task Control					
202	-3	26	44	Fronto-parietal Task Control					
203	11	-39	50	Salience					
204	55	-45	37	Salience					
205	42	-0	47	Salience					
206	31	33	26	Salience					
207	48	22	9,7	Salience					
208	-35	20	0,1	Salience					
209	36	22	2,6	Salience					
210	37	32	-2	Salience					

Supplementary Table 3: Gene primers in DIAN

Gene	Ensembl_Transcript_ID	Exon	Direction	Sequence
PSEN2	ENST00000366783.3	4	Forward	GACAGGCATCTCTTGGAAAGC
		4	Reverse	CATCAGGGAATGAATGTCTGG
		5	Forward	ACTTCTCATTTCTGGTTCCA
		5	Reverse	TAGGTCAACAATCCAGGAGG
		6	Forward	ACTCCATCAGGGCAGCAT
		6	Reverse	AAAAATCTGGGTCTATTTCTCT
		8	Forward	GTTGGGACTGAATGGTGGTA
		8	Reverse	CCCTCTGTTTACAAAGGCG
		9	Forward	AACTCATAGTGACGGGTCTG
		9	Reverse	GTAATAACCCCTCGCTCTCT
PSEN1	ENST00000324501.5	5	Forward	TTGGTGAGTTGGGAAA
		5	Reverse	CACAGTGAGGAGGAAGAAAAA
		6	Forward	CGACAAAGTGAGACCCGT
		6	Reverse	AGTACATGGCTTAAATGATAGCT
		7	Forward	ATGTTGGGAGCCATCA
		7	Reverse	CCAGCCGAAATCTCAA
		8	Forward	TCACCTGCCATTATTCA
		8	Reverse	CAGGAATGCTGTGCATTAA
		9	Forward	CTGCTAAAACCAAAGAGAAC
		9	Reverse	TGTATTTACTGGCATTATCATAG
APP	ENST00000346798.3	11	Forward	AAAACACAGCTGAAGCCTAA
		11	Reverse	GCTCCTCAGATAGCTGGAAT
		12	Forward	TCCAGATTGAATGAACGTCT
		12	Reverse	TGGAAGGAAGCTGCAA
		13	Forward	ATGCTGCCTAATAACCAGTCC
		13	Reverse	TCCCAAGAACCAAGGAAATCAA
		16	Forward	GGTTCCCTTACCCCTTCATT
		16	Reverse	TCAGCCTAGCCTATTATTTCT
		17	Forward	TGAAACTTTTATATAACCTCATCAA
		17	Reverse	CATGGAAGCACACTGATTG

The table is annotated based on Ensembl version 75 in genome build GRCh37

Supplementary Table 4: Gene primers in PREVENT-AD

Gene	Variant	Analyses	Sequence
<i>APOE</i>	rs429358	amplification forward	5'-ACGGCTGTCCAAGGGAGCTG-3'
		amplification reverse biotinylated	5'-CACCTCGCCGCAGTACTG-3'
		sequencing	5'-CGGACATGGAGGACG-3'
	rs7412	amplification forward	5'-CTCCCGCGATGCCGATGAC-3'
		amplification reverse biotinylated	5'-CCCCGGCCTGGTACACTG-3'
		sequencing	5'-CGATGACCTGCAGAAG-3'

Supplementary Methods

Race/ethnicity from the different cohorts

DIAN: The sample mainly identified as non-Hispanic/White, both for mutation non-carriers (90% from the training set and 100% from the test set) and mutation carriers (80% from the test set).

The ten remaining mutation non-carriers (all from the training set) identified as Hispanic/White (n=4), Hispanic with no further specification (n=2), non-Hispanic/Middle Eastern (n=1) or non-Hispanic/Aboriginal (n=2). Regarding the 24 mutation carriers with a different race/ethnicity, they identified themselves as Hispanic/White (n=10), Hispanic with no further specification (n=6), non-Hispanic/Middle Eastern-North Africa (n=2), Aboriginal (n=1), native Hawaiian or other pacific islanders (n=3), Hispanic/Black or African American (n=1) and non-Hispanic/Asian (n=1).

PREVENT-AD: The sample was mainly White/Caucasian with the exception of 4 participants (2 Hispanics, 1 Haitian and 1 unspecified).

ADNI: The sample mainly identified as non-Hispanic/White (83% of those included in the training set and 93% of those included in the test set), with the exception of 6 subjects (1 Hispanic/White, 1 unknown ethnicity/White and 3 non-Hispanic/not White [1 Black, 1 with more than one race and 1 unknown] in the training set, and 1 Hispanic/White in the test set).

FCP-Cambridge, CamCAN and ICBM: Participants from the FCP-Cambridge were recruited from the Cambridge (MA, USA) area, CamCAN is a population-based cohort recruited within the Cambridge City (UK) area (excluding term-time residents of colleges and universities) and the ICBM cohort was recruited in the Montreal (QC, Canada) area; however further demographic information, including specific information on race/ethnicity, was not provided for these cohorts.

Estimated years to symptom onset

Estimated expected years to symptom onset (EYO) was computed in the two cohorts by subtracting each participant's age at assessment from his/her parent's age at symptom onset. In DIAN, the parental age at onset was determined using semi-structured interview in which family members were asked about the age of first progressive cognitive decline.¹ In PREVENT-

AD, EYO was calculated using the age of the parent at which the family observed significant cognitive/memory changes, as reported by the participant during the medical interview.²⁻⁴

We conducted partial correlations between EYO and the predicted age difference (PAD), controlling for the influence of chronological age, in DIAN and PREVENT-AD.

Calculation of small-worldness and resilience

For a thresholded correlation matrix G , small-worldness was calculated as Supplementary Equation 1:

$$\text{small-worldness} = [(\text{clustering}_G / \text{clustering}_{\text{random}}) \\ / (\text{efficiency}_{\text{random}} / \text{efficiency}_G)] \quad (1)$$

in which clustering is the clustering coefficient, and indicates the extent to which nodes are clustered together. The efficiency indicates the average of the inverse path length between nodes of the matrix. The subscript random indicates when these measures are taken on randomly scrambled matrices with preserved degree count for each node in G , and were generated using the function `randmio_und`. Random clustering coefficient and efficiency were averaged over 100 random matrices, generated for each scan.

Resilience is a measure of the robustness of network G as node hubs are removed. Networks with scale-free properties (*i.e.* node degree probabilities follow a power-law distribution) are resilient to random attacks and can be described as Supplementary Equation 2:

$$p(k) \propto k^{-y} \quad (2)$$

where $p(k)$ is the probability of a node having a degree of k (or k total connections), and y is an exponent. On a log-log scale this probability distribution is linear, and thus resilience of G can be estimated as the negative slope of the degree distribution.

Supplementary Notes. DIAN Study Group

Last Name	First	Institution	Affiliation	Core	Role	Email address
Allegri	Ricardo	FLENI	FLENI Institute of Neurological Research (Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia)	N/A	PI	rallegri@fleni.org.ar
Bateman	Randy	WU	Washington University in St. Louis School of Medicine	Admin	Core Leader/PI/Chair	batemanr@wustl.edu
Bechara	Jacob	Sydney	Neuroscience Research Australia	N/A	Site Leader	j.bechara@neura.edu.au
Benzinger	Tammie	WU	Washington University in St. Louis School of Medicine	Imaging	Core Leader	benzingert@wustl.edu
Berman	Sarah	Pitt	University of Pittsburgh	N/A	PI	bermans@upmc.edu
Bodge	Courtney	Butler	Brown University-Butler Hospital	N/A	Site Coordinator	Cbodge@Butler.org
Brandon	Susan	WU	Washington University in St. Louis School of Medicine	Admin / Clinical	Core Personnel	brandons@wustl.edu
Brooks	William (Bill)	Sydney	Neuroscience Research Australia	N/A	Site Coordinator	w.brooks@NeuRA.edu.au
Buck	Jill	IU	Indiana University	N/A	Site Coordinator	jilmbuck@iu.edu
Buckles	Virginia	WU	Washington University in St. Louis School of Medicine	Admin	Core Personnel	bucklesv@wustl.edu
Chea	Sochenda	Mayo	Mayo Clinic Jacksonville	N/A	Site Coordinator	chea.sochenda@mayo.edu
Chhatwal	Jasmeer	BWH	Brigham and Women's Hospital–Massachusetts General Hospital	N/A	PI	Chhatwal.Jasmeer@mgh.harvard.edu
Chrem	Patricio	FLENI	FLENI Institute of Neurological Research (Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia)	N/A	Site Coordinator	pchremmendez@fleni.org.ar
Chui	Helena	USC	University of Southern California	N/A	PI	helena.chui@med.usc.edu
Cinco	Jake	UCL	University College London	N/A	Site Coordinator	jcinco@nhs.net
Cruchaga	Carlos	WU	Washington University in St. Louis School of Medicine	Genetics	Core Co-Leader	cruchagac@wustl.edu
Donahue	Tamara	WU	Washington University in St. Louis School of Medicine	N/A	Site Coordinator	tammie@wustl.edu
Douglas	Jane	UCL	University College London	N/A	Site Coordinator	jdouglas@dementia.ion.ucl.ac.uk

Last Name	First	Institution	Affiliation	Core	Role	Email address
Edigo	Noelia	FLENI	FLENI Institute of Neurological Research (Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia)	N/A	Site Coordinator	negido@fleni.org.ar
Erekin-Taner	Nilufer	Mayo	Mayo Clinic Jacksonville	N/A	sub-l	taner.nilufer@mayo.edu
Fagan	Anne	WU	Washington University in St. Louis School of Medicine	Biomarker	Core Leader	fagana@wustl.edu
Farlow	Marty	IU	Indiana University	N/A	PI	mfarlow@iupui.edu
Fitzpatrick	Colleen	BWH	Brigham and Women's Hospital-Massachusetts	N/A	Site Co-Coordinator	cdfitzpatrick@bwh.harvard.edu
Flynn	Gigi	WU	Washington University in St. Louis School of Medicine	Admin / Clinical	Core Personnel	flynng@wustl.edu
Fox	Nick	UCL	University College London	N/A	PI	nfox@dementia.ion.ucl.ac.uk
Franklin	Erin	WU	Washington University in St. Louis School of Medicine	Neuropath	Core Coordinator	efranklin@wustl.edu
Fujii	Hisako	Japan	Osaka City University	N/A	Assistant/Coord	hfujii@med.osaka-cu.ac.jp
Gant	Cortaiga	WU	Washington University in St. Louis School of Medicine	Admin / Clinical	Core Personnel	cortaiga.gant@wustl.edu
Gardener	Samantha	Perth	Edith Cowan University, Perth	N/A	Site Coordinator	s.gardener@ecu.edu.au
Ghetti	Bernardino	IU	Indiana University	N/A	sub-l	bghetti@iupui.edu
Goate	Alison	Icahn NY	Icahn School of Medicine at Mount Sinai	Genetics	Core Co-Leader	alison.goate@mssm.edu
Goldman	Jill	CU	Columbia University	N/A	Genetics Ethics	JG2673@cumc.columbia.edu
Gordon	Brian	WU	Washington University in St. Louis School of Medicine	Imaging	Core Personnel	bagordon@wustl.edu
Graff-Radford	Neill	Mayo	Mayo Clinic Jacksonville	N/A	PI	graffradford.neill@mayo.edu
Gray	Julia	WU	Washington University in St. Louis School of Medicine	Biomarker	Core Personnel	gray@wustl.edu
Groves	Alexander	WU	Washington University in St. Louis School of Medicine	Biomarker	Core Coordinator	amgroves@wustl.edu
Hassenstab	Jason	WU	Washington University in St. Louis School of Medicine	Clinical	Core Personnel	hassenstabj@wustl.edu
Hoechst-Swisher	Laura	WU	Washington University in St. Louis School of Medicine	Admin / Clinical	Core Coordinator	goodl@wustl.edu

Last Name	First	Institution	Affiliation	Core	Role	Email address
Holtzman	David	WU	Washington University in St. Louis School of Medicine	N/A	Associate Director	holtzman@wustl.edu
Hornbeck	Russ	WU	Washington University in St. Louis School of Medicine	Imaging	Core Coordinator	russ@wustl.edu
Houeland DiBari	Siri	Munich	German Center for Neurodegenerative Diseases (DZNE) Munich	N/A	Site Coordinator	Siri.HouelandDiBari@dzne.de
Ikeuchi	Takeshi	Niigata	Niigata University	N/A	Site Leader	iikeuchi@bri.niigata-u.ac.jp
Ikonomovic	Snezana	Pitt	University of Pittsburgh	N/A	Site Coordinator	ikonomovics@upmc.edu
Jack	Clifford	Mayo	Mayo Clinic Jacksonville	MRI QC	Vendor MRI QC	jack.clifford@mayo.edu
Jerome	Gina	WU	Washington University in St. Louis School of Medicine	Biomarker	Core Coordinator	ginajerome@wustl.edu
Jucker	Mathias	Tubingen	German Center for Neurodegenerative Diseases (DZNE) Tubingen	N/A	PI	mathias.jucker@uni-tuebingen.de
Karch	Celeste	WU	Washington University in St. Louis School of Medicine	Administrative	Core Personnel	karchc@wustl.edu
Kasuga	Kensaku	Niigata	Niigata University	N/A	Site Coordinator	ken39@bri.niigata-u.ac.jp
Kawarabayashi	Takeshi	Hirosaki	Hirosaki University	N/A	Clinician	tkawara@hirosaki-u.ac.jp
Klunk	William (Bill)	Pitt	University of Pittsburgh	N/A	sub-I	klunkwe@gmail.com
Koeppe	Robert	U of Michigan	University of Michigan	PET QC	Vendor PET QC	koeppe@umich.edu
Kuder-Buletta	Elke	Tubingen	German Center for Neurodegenerative Diseases (DZNE) Tubingen	N/A	Site Coordinator	elke.buletta@med.uni-tuebingen.de
Laske	Christoph	Tubingen	German Center for Neurodegenerative Diseases (DZNE) Tubingen	N/A	sub-I	christoph.laske@med.uni-tuebingen.de
Lee	Jae-Hong	Korea	Asan Medical Center	N/A	PI	jhlee@amc.seoul.kr
Levin	Johanne s	Munich	German Center for Neurodegenerative Diseases (DZNE) Munich	N/A	PI	Johannes.Levin@med.uni-muenchen.de
Martins	Ralph	Perth	Edith Cowan University	N/A	PI	r.martins@ecu.edu.au
Mason	Neal Scott	UPMC	University of Pittsburgh Medical Center	PIB QC	Vendor PIB QC	masonss@upmc.edu
Masters	Colin	Melb	University of Melbourne	N/A	PI - former	c.masters@unimelb.edu.au

Last Name	First	Institution	Affiliation	Core	Role	Email address
Maue-Dreyfus	Denise	WU	Washington University in St. Louis School of Medicine	Clinical	Core Personnel	dmdreyfu@wustl.edu
McDade	Eric	WU	Washington University in St. Louis School of Medicine	Clinical	Core Leader Assoc	ericmcdade@wustl.edu
Mori	Hiroshi	Japan	Osaka City University	N/A	PI	mori@med.osaka-cu.ac.jp
Morris	John	WU	Washington University in St. Louis School of Medicine	Clinical	Core Leader	jcmorris@wustl.edu
Nagamatsu	Akem	Tokyo	Tokyo University	N/A	Site Coordinator	akm77-tky@umin.ac.jp
Neimayer	Katie	CU	Columbia University	N/A	Site Coordinator	kn2416@cumc.columbia.edu
Noble	James	CU	Columbia University	N/A	PI	jn2054@columbia.edu
Norton	Joanne	WU	Washington University in St. Louis School of Medicine	Genetics	Core Coordinator	nortonj@wustl.edu
Perrin	Richard	WU	Washington University in St. Louis School of Medicine	Neuropath	Core Leader	rperrin@wustl.edu
Raichle	Marc	WU	Washington University in St. Louis School of Medicine	Imaging	Core Personnel	mraichle@wustl.edu
Renton	Alan	Icahn NY	Icahn School of Medicine at Mount Sinai	Genetics	Core Personnel	alan.renton@mssm.edu
Ringman	John	USC	University of Southern California	N/A	<i>sub-l</i>	john.ringman@med.usc.edu
Roh	Jee Hoon	Korea	Asan Medical Center	N/A	<i>sub-l</i>	roh@amc.seoul.kr
Salloway	Stephen	Butler	Brown University-Butler Hospital	N/A	PI	SSalloway@Butler.org
Schofield	Peter	Sydney	Neuroscience Research Australia	N/A	PI	p.schofield@neura.edu.au
Shimada	Hiroyuki	Osaka	Osaka City University	N/A	<i>Site Leader</i>	h.shimada@med.osaka-cu.ac.jp
Sigurdson	Wendy	WU	Washington University in St. Louis School of Medicine	N/A	Site Coordinator	sigurdsonw@wustl.edu
Sohrabi	Hamid	Perth	Edith Cowan University	N/A	Site Coordinator	h.sohrabi@ecu.edu.au
Sparks	Paige	BWH	Brigham and Women's Hospital-Massachusetts	N/A	Site Coordinator	kpsparks@bwh.harvard.edu
Suzuki	Kazushi	Tokyo	Tokyo University	N/A	<i>Site Leader</i>	kazusuzuki-tky@umin.ac.jp
Taddei	Kevin	Perth	Edith Cowan University	N/A	Site Coordinator	k.taddei@ecu.edu.au
Wang	Peter	WU	Washington University in St. Louis School of Medicine	Biostat	Core Coordinator	guoqiao@wustl.edu
Xiong	Chengjie	WU	Washington University in St. Louis School of Medicine	Biostat	Core Leader	chengjie@wustl.edu

Last Name	First	Institution	Affiliation	Core	Role	Email address
Xu	Xiong	WU	Washington University in St. Louis School of Medicine	Biostat	Core Personnel	xu@wustl.edu
Levey	Allan	Emory	Emory University School of Medicine	N/A	Project Leader	alevy@emory.edu

Supplementary References

1. Bateman, R. J. *et al.* Clinical and biomarker changes in dominantly inherited Alzheimer's disease. *N. Engl. J. Med.* **367**, 795–804 (2012).
2. Villeneuve, S. *et al.* Proximity to Parental Symptom Onset and Amyloid- β Burden in Sporadic Alzheimer Disease. *JAMA Neurol* (2018) doi:10.1001/jamaneurol.2017.5135.
3. Vogel, J. W. *et al.* Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. *Brain* (2018) doi:10.1093/brain/awy093.
4. Gonzeaud, J. *et al.* Association of education with A β burden in preclinical familial and sporadic Alzheimer disease. *Neurology* **95**, e1554–e1564 (2020).